# A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

> **NCT03776175** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 99 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease (NAFLD)

## Interventions

- **DRUG:** PF-05221304 Monotherapy
- **DRUG:** PF-06865571 Monotherapy
- **DRUG:** Placebo
- **DRUG:** PF-05221304 and PF-06865571 Combination

## Key facts

- **NCT ID:** NCT03776175
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-04
- **Primary completion:** 2019-09-09
- **Final completion:** 2019-10-11
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2020-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03776175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03776175, "A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03776175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*